Basics of Chimeric Antigen Receptor (CAR) Immunotherapy
Auteur : Balkhi Mumtaz Y
T cell adoptive immunotherapy has been envisioned to cure metastatic malignant cancers. The recent clinical data obtained with the checkpoint receptor blockade inhibitors and chimeric antigen receptor (CAR) therapy have been especially promising that have generated renewed hope that we may be at the verge of finally curing the cancer. The disease has been devastating families and individuals around the globe. Over the years, huge progress has been made in controlling several stage IV metastasized cancers through the clinical application of checkpoint receptor inhibitory drugs as well as CAR-Therapy that has seem unprecedented interest in the immunotherapy field.
- First book to provide basic understanding of chimeric antigen receptors (CARs) design, production and clinical application protocols
- Provides unique distinction as the editor has working directly with CARs
- Discusses the challenges encountered in actual clinical trials and these challenges can be overcome
- Full chapter dedicated discussing the various challenges expected to encounter in CAR-therapy field
2. Components and design of Chimeric Antigen Receptors (CARs)
3. scFv cloning, vectors and CAR production in laboratory for preclinical application
4. Production of CAR-T cells for clinical application
5. Challenges and opportunities to improve CAR-TE cell therapy
Date de parution : 09-2019
Ouvrage de 166 p.
À paraître, réservez-le dès maintenant
97,13 €Ajouter au panier